INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved INFLECTRAâ„¢ (biosimilar infliximab) ...
-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results